Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ACAM-CDIFF vaccine for prevention of recurrent Clostridioides difficile infection
2008-004907-69Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Clostridioides difficile colitis (CDI) comparing ACAM-CDIFF pooled vaccine groups with Placebo (2 arms). Primary endpoint: CDI event rate after third dose. Started Oct 2008; status: completed.
02
Drugs
ACAM-CDIFF
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2008-004907-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004907-69.